[
    [
        {
            "time": "",
            "original_text": "乐普医疗参股公司旗下企业PD-1创新型单抗药物已进入II期临床试验",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "参股公司",
                    "PD-1",
                    "创新型单抗药物",
                    "II期临床试验"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "乐普医疗参股公司旗下企业PD-1创新型单抗药物已进入II期临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]